Navigation Links
Lincoln Financial Group Expands Panel of Dental Providers, Enhances Optional Dental Benefits
Date:4/6/2009

PHILADELPHIA, April 6 /PRNewswire-FirstCall/ -- The Insurance Solutions division of Lincoln National Corporation (NYSE: LNC) today announced the expansion of its panel of Dental providers. The Lincoln DentalConnect(SM) PPO plan increased the number of providers so the panel now includes more than 54,000 unique providers and over 95,000 provider locations, offering greater choices for affordable, local dental care. The newly expanded panel of Dental providers is immediately available via Lincoln's website link.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050830/LFLOGO )

"We're committed to making quality dental care accessible to our customers," said Dave Swanson, Vice President of Product Development for Lincoln Insurance Solutions, Group Protection. "By expanding our provider and provider location list, we're helping ensure customers can easily find a skilled dentist in their local area."

Additionally, the Lincoln DentalConnect(SM) PPO plan now offers an enhanced selection of optional benefit coverages. Dental implants and composite posterior fillings are available as optional coverage for groups with effective dates of April 1, 2009 or later.

To review the expanded panel of dental providers and/or additional information about Lincoln's full portfolio of employee benefit products - including Lincoln DentalConnectSM PPO- visit www.LincolnFinancial.com/dentist.

Group insurance products are issued by The Lincoln National Life Insurance Company (Fort Wayne, IN), which does not s
'/>"/>

SOURCE Lincoln Financial Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Lincoln Park Zoo researcher awarded prestigious conservation biology fellowship
2. Lincoln Park Performing Arts Center to Host Highly Acclaimed Music and Medicine Program
3. Grifols Biomat USA Opens New Plasma Donor Center in Lincoln
4. Lincoln Financial Group Announces New Dental Panel of Providers
5. Lincoln Financial Group Launches Lincoln 403(b)e SURE(SM) Advantage
6. Home Oxygen Community Applauds Senator Blanche Lincoln for Leading Bi-Partisan Effort to Formally Oppose Proposed Cuts to Medicares Home Oxygen Benefit
7. Abraham Lincoln Presenter to Speak in Tulsa This Saturday
8. Lincoln Financial Advisors to Provide Exclusive Services to American Osteopathic Association Members
9. Gold Standard for Lice Removal Opens in Lincoln Park to Save School System $2.5 million
10. Craneware to Offer Financial Performance Solutions to Hospitals and Healthcare Providers Through Premier, the Largest U.S. Healthcare Alliance
11. Boston Scientific to Webcast Conference Call Discussing First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Procter & Gamble Announces Appointment of Director 2Health News:Possible ovarian cancer treatment target identified 2Health News:Testosterone Gets Bad Rap: Study 2Health News:Testosterone Gets Bad Rap: Study 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21
Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 1Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 2Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 3Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 4Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 1Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 2Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 3Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 1Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 2Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 3Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 4
Other Medicine Technology:New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 2Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 3